Evidence map›Paper›PMID 12390056›Full record

Trial reportDrugs & aging2002

Health-related quality of life and long-term therapy with pravastatin and tocopherol (vitamin E) in older adults.

Cynthia M Carlsson, Kristi Papcke-Benson, Molly Carnes, Patrick E McBride, James H Stein

Abstract readClinical TrialRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Drugs & aging, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 9 pooled it
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 9 syntheses or guidelines pooled it, 40 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Vitamin E for Alzheimer's dementia and mild cognitive impairment.The Cochrane database of systematic reviews · 2017
    Pooled it
  5. Vitamin E for Alzheimer's dementia and mild cognitive impairment.The Cochrane database of systematic reviews · 2017
    Pooled it
  6. Pooled it
  7. Statins, mood, sleep, and physical function: a systematic review.European journal of clinical pharmacology · 2014
    Pooled it
  8. Vitamin E for Alzheimer's dementia and mild cognitive impairment.The Cochrane database of systematic reviews · 2012
    Pooled it
  9. Pooled it
  10. Trial
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Nutrition in the age-related disablement process.The journal of nutrition, health & aging · 2011
    Review
  18. Review
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Cynthia M CarlssonUniversity of Wisconsin Medical School, Madison, Wisconsin 53792, USA.
Kristi Papcke-Benson
Molly Carnes
Patrick E McBride
James H Stein
University of Wisconsin–Madison · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionConcerns about the effects of HMG-CoA reductase inhibitors ('statins') on health-related quality of life may contribute to their underuse in older adults with and at risk for cardiovascular disease. These concerns also may prevent clinicians from enrolling older patients in clinical trials assessing the efficacy of statins as a preventive therapy for Alzheimer's disease.

objectiveTo determine the effects of pravastatin and tocopherol (vitamin E), alone and in combination, on health-related quality of life in older adults. STUDY

designDouble-blind, randomised, placebo-controlled, crossover study.

participantsForty-one community-dwelling men and women aged > or = 70 years with low-density lipoprotein-cholesterol (LDL-C) > or = 3.62 mmol/L (140 mg/dl) participated.

methodsSubjects received pravastatin for 6 months then pravastatin plus tocopherol for an additional 6 months (group 1), or tocopherol for 6 months then pravastatin plus tocopherol for an additional 6 months (group 2). Dosages were pravastatin 20 mg daily and tocopherol 400 IU daily.

main outcome measuresThe following health-related quality-of-life measures were assessed at baseline, after 6 months and after 1 year: health perception, depression, physical function, cognitive function and sleep behaviour. In addition, data on adverse effects and laboratory abnormalities were obtained.

resultsPravastatin reduced levels of total cholesterol (-21%, p < 0.001) and LDL-C (-29%, p < 0.001). Health-related quality-of-life scores, physical adverse effects, muscle enzyme levels and liver function tests did not change after 12 months of therapy with pravastatin, tocopherol or their combination.

conclusionBoth pravastatin and tocopherol have a good safety profile, are well tolerated and do not adversely affect health-related quality of life in older patients with hypercholesterolaemia. Given the significant beneficial cardiovascular effects of statin therapy in older adults and the potential role of statins in prevention of Alzheimer's disease, concerns about adverse effects on quality of life should not deter use of these medications in this population.

Indexed as

AgedAged, 80 and overCholesterol, HDLCholesterol, LDLCross-Over StudiesDouble-Blind MethodDrug Therapy, CombinationFemaleHeart RateHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaHypolipidemic AgentsMaleMiddle AgedPravastatinCholesterol, HDLCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsHypolipidemic AgentsPravastatinTocopherolsTriglycerides

Identifiers

PMID12390056
OpenAlexW2047026973

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.